For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126 (Public Relations)
+81-3-6225-1125 (Investor Relations)
http://www.daiichisankyo.com/

The Japan Research Foundation for Clinical Pharmacology, A Daiichi Sankyo Foundation, has awarded Third Annual Clinical Pharmacology Research Award

Tokyo, Japan (June 14, 2010) – Daiichi Sankyo Company, Limited announced that its affiliate, the Japan Research Foundation for Clinical Pharmacology (headquarters: Tokyo, Director General: Kiyoshi Morita) has awarded its third “Japan Research Foundation for Clinical Pharmacology Research Award” to five young researchers this year.

 

Awardees are selected from research papers submitted from projects funded with subsidies from the foundation. Innovative research projects with expectations for future development are eligible for the award.

 

The Foundation hopes that the award will motivate young researchers in clinical pharmacology involved in establishment of appropriate drug treatments and encourage future research results. The awards ceremony and presentations of the research themes will be held on November 8, 2010.

 

The mission of the Foundation is to promote clinical pharmacology and foster the development of clinical pharmacologists. The Foundation was established in 1975 and in its 35 year history it has worked on a variety of projects relating to clinical pharmacology, including promotion of research, overseas studies for Japanese researchers and Asian international collaborations.

 

 

Third Japan Research Foundation for Clinical Pharmacology Research Awardees

 

Awardees	Organization	Research theme
Hideyuki Takeuchi	Department of Neuroimmunology, Research Institute of Environmental Medicine,　Nagoya University	Development of microglia-targeting therapy against amyotrophic lateral sclerosis.
Hideto To	Department of Hospital Parmacy, Nagasaki University Hospital	Chronotherapy of methotrexate in patients with rheumatoid arthritis.
Shinpei Nonen	Department of Clinical Pharmacology and PharmacogenomicsGraduate School of Pharmaceutical Sciences, Osaka University（Present）Department of Pharmacy　Hyogo University of Health Sciences	Thrombospondin 1 polymorphism(Thr523Ala) is associated with the response to  β-blockers in the patients with heart failure.
Kazuya Maeda	Laboratory of Molecular　Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo	Search for probe drugs for the in vivo phenotyping of transport activities of organic anion transporter(OAT)1 and OAT3 in human kidney.
Hiromichi Wada	Division of Translational Research National Hospital Organization Kyoto Medical Center	Significance of serum soluble VEGF receptor-2 levels in chronic heart failure patients with left ventricular hypertrophy.